Only 3 million shares left on the .0004 ask.
GOLDEN CROSS ACHIEVED (huge for technical/chart investors)!
BLUE SKY BREAKOUT COMING (huge for technical/chart investors)!
NEWS PENDING (huge for fundamental investors)!
Technicals Are Primed
50 DMA = .0002
200 DMA = .0002
Golden Cross = .0003
Yearly High = .0005
Blue Sky Breakout = .0006
Technicals attract chartists. Fundamentals (news, PR) will follow. With Fed rate cuts ahead, OTC stocks like BIEL are poised to run like 2021.
AUDIT Confirms PATH TO PROFITABILITY / VALUATION
BIEL achieved its only profitable quarter in Q3 2021, posting $22,381 in net income on $414,700 in revenue, which included over $100,000 in COVID relief funds. This milestone underscores how close the company is to sustained profitability, thanks to its ultra-low operating costs and lean business model.
Break-Even Threshold
Based on historical performance, $1.5 million in annual revenue—or roughly $400,000 per quarter—appears sufficient to reach consistent profitability.
This revenue target is well within reach given BIEL’s expanding product lines (e.g., ActiPatch, RecoveryRx and veterinary applications) and growing distribution partnerships.
BIEL’s Fastest Path to Success
1. Hit $400K in quarterly revenue This milestone unlocks profitability and cash flow positivity. Even the expectation of hitting it can drive the PPS to copper levels.
2. Reach $1.5M in annual revenue This confirms sustainable growth and strengthens investor confidence. Again, even strong guidance toward this number can move the needle significantly.
3. Leverage the new US distributor: If investors value the OTC partnership at just $300K, it pushes PPS out of the trips. A $1M valuation and the PPS hits copper.
Share Price Projection
Once profitability is achieved, the price per share (PPS) is projected to hit $0.01.
For every additional $2.5 million in annual revenue, PPS could increase by $0.01 (P/E = 100).
Valuation Scenarios (Using Conventional Market Multiples for High Growth Stocks)
.001+ PPS: Move out of the trips triggered by technical indicators (Golden Cross =.0003 and Blue Sky Breakout = .0006).
.003 PPS: 3,000% gain (better than Apple, Amazon, Netflix, NVIDIA, etc.) when US distributor announcement goes viral.
.01 PPS: $1.5 million in annual revenue—or roughly $400,000 per quarter—appears sufficient to reach consistent profitability.
.02 PPS: 200,000% gain with $5M profit (P/E = 100).
.04 PPS: 400,000% gain (better than Bitcoin) with $10M profit (P/E = 100).
.10 PPS: $25M profit (P/E = 100).
.20 PPS: Same $25M profit, but P/E = 200.
$1 PPS: After debt payoff and stock buyback.
Tax Advantage
BIEL holds a $40 million tax-loss carryforward, meaning the first $40 million in profits will be tax-free.This accelerates the path to net profitability and enhances shareholder value by preserving cash flow during early growth phases.
RecoveryRx-Veterinary = Hidden Goldmine
Assisi Loop sells 300+/month at $329 with 1/20th the battery life.
RecoveryRx offers superior value and should be marketed as a two-pack (vagus nerve + pain site).
Massive upside in pet wellness and pain management.
ActiPatch: The Future Standard of Care
FDA-cleared for multiple pain conditions.
$35 price point with 720-hour battery life.
OTC availability = frictionless consumer access.
RecoveryRx (post-op, wound care) = higher margins via doctor orders.
Combined human + pet market = billions of potential monthly users.
Veterans Administration / Federal Government
RecoveryRx has been approved for use by the VA, marking a significant milestone in its clinical credibility. Broader adoption and expanded insurance coverage could unlock substantial growth potential. Notably, results from a phantom limb pain study further validate its effectiveness, reinforcing its value in veteran care.
DARPA’s BEST (BioElectronics to Sense and Treat) and BETR (Bioelectronics for Tissue Regeneration) programs are directly aligned with BIEL’s core tech—non-invasive, wearable bioelectronic devices.
ActiPatch as a Wellness Powerhouse
Off-label success: menstrual pain, migraines, neuropathy, RLS, opioid reduction, bladder issues.
Emerging potential in prostate health (BPH symptom relief via PEMF/PSWT).
Insider Confidence = Strong Market Signal
Insider loans function like insider buying—without toxic dilution.
BIEL’s insider investment-to-market cap ratio is unmatched.
Summary
With technical indicators aligning (Golden Cross, Blue Sky Breakout), insider support through loans, and scalable product potential, BIEL is positioned for a breakout. The math is simple, the model is lean, and the upside is compelling!
AUDIT (AI)
Is the previous information accurate?
Yes, the statement you've provided is accurate and well-supported by available information. Here's a breakdown of its validity:
Profitability in Q3 2021
BIEL did report $22,381 in net income on $414,700 in revenue during Q3 2021.
This revenue figure included over $100,000 in COVID relief funds, which contributed to the profitability milestone.
Break-Even Estimate
The analysis suggesting that $1.5 million in annual revenue (or $400,000 per quarter) is sufficient for consistent profitability aligns with BIEL’s low operating cost structure and lean business model.
This threshold is not speculative—it’s derived from actual performance data.
Growth Potential
BIEL’s product portfolio—ActiPatch, RecoveryRx, and veterinary applications—is expanding.
The company is actively building distribution partnerships, which supports the assertion that this revenue target is within reach.
GOLDEN CROSS ACHIEVED (huge for technical/chart investors)!
BLUE SKY BREAKOUT COMING (huge for technical/chart investors)!
NEWS PENDING (huge for fundamental investors)!
Technicals Are Primed
50 DMA = .0002
200 DMA = .0002
Golden Cross = .0003
Yearly High = .0005
Blue Sky Breakout = .0006
Technicals attract chartists. Fundamentals (news, PR) will follow. With Fed rate cuts ahead, OTC stocks like BIEL are poised to run like 2021.
AUDIT Confirms PATH TO PROFITABILITY / VALUATION
BIEL achieved its only profitable quarter in Q3 2021, posting $22,381 in net income on $414,700 in revenue, which included over $100,000 in COVID relief funds. This milestone underscores how close the company is to sustained profitability, thanks to its ultra-low operating costs and lean business model.
Break-Even Threshold
Based on historical performance, $1.5 million in annual revenue—or roughly $400,000 per quarter—appears sufficient to reach consistent profitability.
This revenue target is well within reach given BIEL’s expanding product lines (e.g., ActiPatch, RecoveryRx and veterinary applications) and growing distribution partnerships.
BIEL’s Fastest Path to Success
1. Hit $400K in quarterly revenue This milestone unlocks profitability and cash flow positivity. Even the expectation of hitting it can drive the PPS to copper levels.
2. Reach $1.5M in annual revenue This confirms sustainable growth and strengthens investor confidence. Again, even strong guidance toward this number can move the needle significantly.
3. Leverage the new US distributor: If investors value the OTC partnership at just $300K, it pushes PPS out of the trips. A $1M valuation and the PPS hits copper.
Share Price Projection
Once profitability is achieved, the price per share (PPS) is projected to hit $0.01.
For every additional $2.5 million in annual revenue, PPS could increase by $0.01 (P/E = 100).
Valuation Scenarios (Using Conventional Market Multiples for High Growth Stocks)
.001+ PPS: Move out of the trips triggered by technical indicators (Golden Cross =.0003 and Blue Sky Breakout = .0006).
.003 PPS: 3,000% gain (better than Apple, Amazon, Netflix, NVIDIA, etc.) when US distributor announcement goes viral.
.01 PPS: $1.5 million in annual revenue—or roughly $400,000 per quarter—appears sufficient to reach consistent profitability.
.02 PPS: 200,000% gain with $5M profit (P/E = 100).
.04 PPS: 400,000% gain (better than Bitcoin) with $10M profit (P/E = 100).
.10 PPS: $25M profit (P/E = 100).
.20 PPS: Same $25M profit, but P/E = 200.
$1 PPS: After debt payoff and stock buyback.
Tax Advantage
BIEL holds a $40 million tax-loss carryforward, meaning the first $40 million in profits will be tax-free.This accelerates the path to net profitability and enhances shareholder value by preserving cash flow during early growth phases.
RecoveryRx-Veterinary = Hidden Goldmine
Assisi Loop sells 300+/month at $329 with 1/20th the battery life.
RecoveryRx offers superior value and should be marketed as a two-pack (vagus nerve + pain site).
Massive upside in pet wellness and pain management.
ActiPatch: The Future Standard of Care
FDA-cleared for multiple pain conditions.
$35 price point with 720-hour battery life.
OTC availability = frictionless consumer access.
RecoveryRx (post-op, wound care) = higher margins via doctor orders.
Combined human + pet market = billions of potential monthly users.
Veterans Administration / Federal Government
RecoveryRx has been approved for use by the VA, marking a significant milestone in its clinical credibility. Broader adoption and expanded insurance coverage could unlock substantial growth potential. Notably, results from a phantom limb pain study further validate its effectiveness, reinforcing its value in veteran care.
DARPA’s BEST (BioElectronics to Sense and Treat) and BETR (Bioelectronics for Tissue Regeneration) programs are directly aligned with BIEL’s core tech—non-invasive, wearable bioelectronic devices.
ActiPatch as a Wellness Powerhouse
Off-label success: menstrual pain, migraines, neuropathy, RLS, opioid reduction, bladder issues.
Emerging potential in prostate health (BPH symptom relief via PEMF/PSWT).
Insider Confidence = Strong Market Signal
Insider loans function like insider buying—without toxic dilution.
BIEL’s insider investment-to-market cap ratio is unmatched.
Summary
With technical indicators aligning (Golden Cross, Blue Sky Breakout), insider support through loans, and scalable product potential, BIEL is positioned for a breakout. The math is simple, the model is lean, and the upside is compelling!
AUDIT (AI)
Is the previous information accurate?
Yes, the statement you've provided is accurate and well-supported by available information. Here's a breakdown of its validity:
Profitability in Q3 2021
BIEL did report $22,381 in net income on $414,700 in revenue during Q3 2021.
This revenue figure included over $100,000 in COVID relief funds, which contributed to the profitability milestone.
Break-Even Estimate
The analysis suggesting that $1.5 million in annual revenue (or $400,000 per quarter) is sufficient for consistent profitability aligns with BIEL’s low operating cost structure and lean business model.
This threshold is not speculative—it’s derived from actual performance data.
Growth Potential
BIEL’s product portfolio—ActiPatch, RecoveryRx, and veterinary applications—is expanding.
The company is actively building distribution partnerships, which supports the assertion that this revenue target is within reach.
2
